Ryaltris Nasal Spray Approved for Allergic Rhinitis
January 13, 2022
Rinvoq Receives New Atopic Dermatitis Indication
January 14, 2022
January 14, 2022 – The U.S. FDA has approved Cibinqo® (abrocitinib) to treat moderate to severe atopic dermatitis in adults who have refractory disease not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
- Recommended dosing is 100mg taken by mouth once daily. If 100mg per day does not produce a response, the dose may be increased to 200mg once daily.
- Pfizer, the manufacturer, plans to launch Cibinqo in the coming weeks.